Venture financing ticks up for biopharma
But, with an ever-growing proportion of the cash going to a select few, the gulf between the haves and the have-nots is widening.
Biopharma's flotation haul creeps higher
Life is returning to the IPO scene, but the recovery is slow and uncertain.
Medtech dealmaking grinds almost to a halt
M&A moves are down, venture rounds few and IPOs nonexistent.
Orbital shows 2023’s venture funding scene is far from stratospheric
The group’s $270m series A, big for 2023, is not that impressive compared with other years.
Sofinnova goes digital
The promise of fast timelines and early revenues lure a new investor into digital medicine.
Floating biotechs prompt tiny sparks of hope
But with only four IPOs so far this year, there is no disguising a moribund market.
Biopharma stocks go back to bleak
Hopes for a better 2023 look optimistic as markets take another turn for the worse.
A lean first quarter for venture-backed developers
While venture investors keep the purse strings tight, they themselves continue to enjoy fundraising success.